All In Biotech

Drug Trial Radar · NCT07425899

A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants

A Phase 1 Study to Evaluate the Pharmacokinetic Interaction and Safety of ABBV-722 and Upadacitinib Following Multiple Oral Doses in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Feb 26, 2026

Primary completion

Jun 5, 2026

Study completion Jun 5, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1 study to investigate safety and pharmacokinetics of ABBV-722 and Upadacitinib following multiple oral doses in healthy adult participants.

Conditions

  • Healthy Volunteer

Interventions

  • ABBV-722Drug

    Oral

  • UpadacitinibDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration at steady state (Cmax,ss) of ABBV-722Time frame: Up to Day 6 in Period 2 and Up to Day 17 in Period 3
  2. Time to maximum observed plasma concentration (Tmax) of ABBV-722Time frame: Up to Day 6 in Period 2 and Up to Day 17 in Period 3
  3. Area under curve over the dosing interval at steady state (AUCtau,ss) of ABBV-722Time frame: Up to Day 6 in Period 2 and Up to Day 17 in Period 3
  4. Observed plasma concentration at the end of the dosing interval at steady state (Ctrough,ss) of ABBV-722Time frame: Up to Day 6 in Period 2 and Up to Day 17 in Period 3
  5. Maximum observed plasma concentration at steady state (Cmax,ss) of UpadacitinibTime frame: Up to Day 7 in Period 1 and Up to Day 17 in Period 3
  6. Time to maximum observed plasma concentration (Tmax) of UpadacitinibTime frame: Up to Day 7 in Period 1 and Up to Day 17 in Period 3
  7. Area under curve over the dosing interval at steady state (AUCtau,ss) of UpadacitinibTime frame: Up to Day 7 in Period 1 and Up to Day 17 in Period 3
  8. Observed plasma concentration at the end of the dosing interval at steady state (Ctrough,ss) of UpadacitinibTime frame: Up to Day 7 in Period 1 and Up to Day 17 in Period 3
  9. Number of Participants with Adverse Events (AEs)Time frame: Approximately up to 91 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Acpru /Id# 279285

    Grayslake, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.